A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis

Badorrek, Philipp; Dick, Melanie; Schauerte, A; Hecker, Hartmut; Murdoch, Robert; Luettig, Birgit; Hohlfeld, JM; Krug, Norbert

doi:10.5414/cpp47071

Cited by 25 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The chosen pollen concentration mimics the natural condition because pollen counts of several thousands per cubic metre have been reported when measurements are performed over a meadow [19] (and own unpublished data). It is important to note that the study population was not pre‐selected according to their symptom scores during a screening exposure visit, which explains why the average TNSS is lower compared with other ECC studies where pre‐selection of responders is part of the screening procedure in order to reduce the variability of the outcome measure [20, 21].…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions

Hohlfeld¹,

Holland‐Letz²,

Larbig³

et al. 2010

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions

Hohlfeld¹,

Holland‐Letz²,

Larbig³

et al. 2010

Clin Experimental Allergy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Depending on the severity of disease, the mainstay treatments for AR are oral or topical H1-antihistamines and intranasal corticosteroids (INS), with INS reported to be the most efficacious currently available treatment [7,8]. Despite treatment, many patients may still suffer some residual symptoms [9,10], and it has been reported that up to 1 in 5 patients with AR remain symptomatic when treated with the best available pharmacotherapy [11].…”

Section: Introductionmentioning

confidence: 99%

The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis

Bareille¹,

Murdoch²,

Denyer³

et al. 2013

View full text Add to dashboard Cite

show abstract

“…An example of a typical study design for evaluating an acute treatment effect is a double‐blind, placebo‐controlled, four‐way crossover study, in which placebo, an antihistamine, a decongestant or a combination of both was given 2 hours after starting the allergen challenge in the ACC . Within the first hour following the treatment, a clear separation of the TNSS was seen in the different treatment arms (Fig.…”

Section: Experience With the Fraunhofer Challenge Chambermentioning

confidence: 99%

Experience with an allergen challenge chamber for clinical trials in allergic rhinitis

2012

Self Cite

View full text Add to dashboard Cite

Allergic rhinitis has the greatest prevalence of any respiratory disease and affects about 20% of the population in North America and Europe. There is an increasing need for allergen challenge systems to test anti-allergic drugs under well-controlled conditions. The allergen challenge chamber (ACC) is a room that enables reproducible challenges with controlled levels of inhalant allergens, temperature and humidity for several hours. ACCs have been used in Europe, North America and Japan to evaluate symptomatic and anti-inflammatory medications for the treatment of allergic rhinitis. This review summarizes the experience with a typical ACC in Germany, the Fraunhofer Challenge Chamber, and describes the stability and reproducibility of the allergen exposure in the chamber. It further provides data for the specificity and reproducibility of clinical read-out parameters, such as nasal symptom scores, nasal flow rates and nasal secretions, as well as of nasal biomarkers obtained in different validation studies. Typical study designs for testing the acute and prophylactic treatment effects of anti-allergic substances are discussed. Regulatory authorities, such as the FDA and EMA, recommend the use of ACCs in drug development to evaluate the optimal dose and onset of action during early clinical development. In combination with natural-exposure Phase III studies, they provide supportive evidence of superiority over placebo as an additional pharmacodynamic assessment tool. In particular, ACC studies may be of additional value in the clinical development of immunotherapy, because the variability of natural allergen exposure hampers the demonstration of efficacy in clinical trials

show abstract

A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis

Abstract: Antihistamines and nasal decongestants are well-established therapeutics in allergic rhinitis. However, no data are available which directly compare the effect size of the single substances with their combination in a single study including placebo (PLA) treatment.

Cited by 25 publications

References 0 publications

Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions

Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions

The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis

Experience with an allergen challenge chamber for clinical trials in allergic rhinitis

Contact Info

Product

Resources

About